A Phase 3 interventional study of standard therapy and Everolimus in Lung Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial evaluated the efficacy of an everolimus-based quadruple low immunosuppressive regimen versus a standard immunosuppressive regimen concerning kidney function in lung transplant recipients.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
Drug: Everolimus
centre specific CNI-based triple drug immunosuppression (IS)
Drug: standard therapy
centre specific CNI-based triple drug immunosuppression
quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
Also known as: RAD001
Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months
Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 months The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1
Time frame: Month 12
Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9, 12
Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9 and 12. The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1
Time frame: Month 1, 3, 6, 9, 12
Calculated Glomerular Filtration Rate (cGFR) According to Cystatin C-based Hoek's Formula at Month 1, 3, 6, 9, 12
Calculated Glomerular Filtration Rate (cGFR) according to Cystatin C-based Hoek's formula at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12
Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12 cGFR (in mL/min/1.73 m2) = 186.3\*(C-1.154)\*(A-0.203)\*G\*R where C = the serum concentration of creatinine (mg/dL), A = age (years), G = 0.742 when gender is female, otherwise G = 1, R = 1.21 when race is black, otherwise R = 1.
Time frame: Month 1, 3, 6, 9, 12
Calculated Glomerular Filtration Rate (cGFR) According to Cockcroft-Gault at Month 1, 3, 6, 9, 12
Calculated Glomerular Filtration Rate (cGFR) according to Cockcroft-Gault at Month 1, 3, 6, 9, 12 For men: GFR=(140-Age) x Body weight (kg) / 72 x Serum Creatinine (mg/dl) For women: GFR=0.85 (140 -Age) x Body weight(kg)/ 72 x Serum Creatinine (mg/dl)
Time frame: Month 1, 3, 6, 9, 12
Incidence of Patients Experiencing a Decline in GFR of < 10, 10-15, 15-20, 20-25 and > 25 mL/Min From Baseline to Month 6 and 12.
Incidence of patients experiencing a decline in GFR of \< 10, 10-15, 15-20, 20-25 and \> 25 mL/min from Baseline to Month 6 and 12calculated by the CKD-EPI method. Participants are counted in each decline level observed for that participant; this means participants may be counted in more than 1 decline level.
Time frame: Baseline, Month 6, Month 12
Incidence of Renal Replacement Therapy at Month 6 and Month 12
Incidence of renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required
Time frame: Month 6, Month 12
Time to Renal Replacement Therapy at Month 6 and Month 12
Time to renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required
Time frame: Month 6, Month 12
Incidence of Acute Rejection Episodes at Month 6 and Month 12
Incidence of acute rejection episodes at Month 6 and Month 12. This table counts multiple occurrences of rejection in the same patient as different incidents. Every incident is associated with both an A and a B classification. Classification A: Acute Rejection Grade 0 - none, Grade 1-minimal, Grade 2- mild, Grade 3-moderate, Grade 4-Severe; Classification B: Airway Inflammation-Grade 0-none, Grade 1R-low grade, Grade 2R-high grade, Grade X-ungradeable
Time frame: Month 6, Month 12
Incidence of Graft Loss/Re-transplantation at Month 6 and Month 12
Incidence of graft loss/re-transplantation at Month 6 and Month 12
Time frame: Month 6, Month 12
Incidence of Bronchiolitis Obliterans Syndrome (BOS) at Month 6 and Month 12
Incidence of Bronchiolitis obliterans syndrome (BOS) at Month 6 and Month 12 BOS 0 is FEV1 \> 90% of baseline and FEF25-75% \> 75% of baseline; BOS 0-p is FEV1 81-90% of baseline and/or FEF25-75% ≤ 75% of baseline; BOS 1 is FEV1 66-80% of baseline; BOS 2 is FEV1 51-65% of baseline; BOS 3 is FEV1 ≤ 50% of baseline
Time frame: Month 6, Month 12
Incidence of Death at Month 6 and Month 12
Incidence of death at Month 6 and Month 12
Time frame: Month 6, Month 12
Quality of Life (QoL, SF36) at Month 6 and Month 12
Quality of Life (QoL, SF36) at Month 6 and Month 12 Scores can range from a minimum of 0 (maximum disability) to a maximum of 100 (no disability).
Time frame: Month 6, Month 12
Exercise Capacity 6-Minute Walk Test(6MWT) at Month 6 and Month 12
Exercise capacity (6MWT) at Month 6 and Month 12 Measured by the Borg Scale. THE BORG SCALE 0 is Nothing at all, 0.5 is Very, very slight (just noticeable); 1 is Very slight, 2 is Slight (light); 3 is Moderate; 4 is Somewhat severe; 5 is Severe (heavy), 7 is Very severe, 10 is Very, very severe (maximal)The higher the Borg score implies increased shortness of breath and/or increased fatigue.
Time frame: Month 6, Month 12
Incidence of Treated Arterial Hypertension up to Month 12
Incidence of treated of arterial hypertension up to Month 12
Time frame: up to Month 12
Incidence of Diabetes Mellitus up to Month 12
Incidence of Diabetes Mellitus up to Month 12
Time frame: up to Month 12
Trough Levels of Everolimus at Month 1, 3, 6, 9, 12
Trough levels of everolimus at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Adherence to Target Ranges of Everolimus at Month 1, 3, 6, 9, 12
Adherence to target ranges of everolimus at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Trough Levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
Trough levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Adherence to Target Ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
Adherence to target ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Trough Levels of Tacrolimus at Month 1, 3, 6, 9, 12
Trough levels of Tacrolimus at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Adherence to Target Ranges of Tacrolimus at Month 1, 3, 6, 9, 12
Adherence to target ranges of Tacrolimus at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Incidence of Bacterial, Viral, and Fungal Infections at Month 12
Incidence of bacterial, viral, and fungal infections at Month 12
Time frame: Month 12
Triglyceride Levels at Month 1, 3, 6, 9, 12
Triglyceride levels at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Total Cholesterol Levels at Month 1, 3, 6, 9, 12
Total Cholesterol levels at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
Low-Density Lipoprotein (LDL)Cholesterol Levels at Month 1, 3, 6, 9, 12
LDL Cholesterol levels at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
High-Density Lipoprotein (HDL)Cholesterol Levels at Month 1, 3, 6, 9, 12
HDL Cholesterol levels at Month 1, 3, 6, 9, 12
Time frame: Month 1, 3, 6, 9, 12
232 patients who were de novo lung transplant recipients were planned for enrolling into the study. A total of 130 patients were actually randomized with 67 patients randomized to the quadruple low-level treatment arm and 63 patients randomized to the center-specific triple treatment arm.
| Milestone | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Started | 67 | 63 |
| Completed | 63 | 61 |
| Not completed | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Graft loss/retransplantation | 1 | 0 |
| Withdrew: Non-specified reason | 0 | 2 |
Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 months The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1
| mL/min | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months | 64.5 ± 16.3 | 54.6 ± 14.3 |
Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9 and 12. The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1
| mL/min | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 73.5 ± 13.9 | 67.1 ± 12.4 |
| Month 3 | 70.4 ± 13.3 | 64.3 ± 12.7 |
| Month 6 | 69.2 ± 15.5 | 63.1 ± 15.0 |
| Month 9 | 69.0 ± 16.3 | 62.3 ± 14.8 |
| Month 12 | 68.3 ± 16.3 | 61.2 ± 14.3 |
Calculated Glomerular Filtration Rate (cGFR) according to Cystatin C-based Hoek's formula at Month 1, 3, 6, 9, 12
| mL/min | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 68.5 ± 14.6 | 61.8 ± 12.8 |
| Month 3 | 65.7 ± 15.2 | 60.3 ± 10.6 |
| Month 6 | 63.0 ± 15.1 | 58.7 ± 12.2 |
| Month 9 | 61.8 ± 14.1 | 57.7 ± 12.8 |
| Month 12 | 60.8 ± 14.2 | 57.5 ± 14.1 |
Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12 cGFR (in mL/min/1.73 m2) = 186.3\*(C-1.154)\*(A-0.203)\*G\*R where C = the serum concentration of creatinine (mg/dL), A = age (years), G = 0.742 when gender is female, otherwise G = 1, R = 1.21 when race is black, otherwise R = 1.
| mL/min | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 72.0 ± 13.5 | 65.8 ± 11.8 |
| Month 3 | 68.7 ± 12.2 | 63.3 ± 12.3 |
| Month 6 | 67.6 ± 14.1 | 62.3 ± 15.0 |
| Month 9 | 67.4 ± 14.9 | 61.7 ± 15.1 |
| Month 12 | 67.0 ± 14.8 | 60.5 ± 14.4 |
Calculated Glomerular Filtration Rate (cGFR) according to Cockcroft-Gault at Month 1, 3, 6, 9, 12 For men: GFR=(140-Age) x Body weight (kg) / 72 x Serum Creatinine (mg/dl) For women: GFR=0.85 (140 -Age) x Body weight(kg)/ 72 x Serum Creatinine (mg/dl)
| mL/min | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 78.6 ± 19.2 | 72.1 ± 14.9 |
| Month 3 | 76.1 ± 17.6 | 70.1 ± 16.0 |
| Month 6 | 76.2 ± 19.3 | 69.1 ± 17.5 |
| Month 9 | 76.2 ± 20.1 | 69.0 ± 18.2 |
| Month 12 | 76.2 ± 20.6 | 68.4 ± 17.8 |
Incidence of patients experiencing a decline in GFR of \< 10, 10-15, 15-20, 20-25 and \> 25 mL/min from Baseline to Month 6 and 12calculated by the CKD-EPI method. Participants are counted in each decline level observed for that participant; this means participants may be counted in more than 1 decline level.
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Up to Month 6: < 10 mL/min | 28 | 44 |
| Up to Month 6: 10 - < 15 mL/min | 9 | 18 |
| Up to Month 6: 15 - < 20 mL/min | 6 | 11 |
| Up to Month 6: 20 - < 25 mL/min | 2 | 7 |
| Up to Month 6: > 25 mL/min | 3 | 7 |
| Up to Month 12: < 10 mL/min | 36 | 53 |
| Up to Month 12: 10 - < 15 mL/min | 10 | 27 |
| Up to Month 12: 15 - < 20 mL/min | 8 | 18 |
| Up to Month 12: 20 - < 25 mL/min | 8 | 9 |
| Up to Month 12: > 25 mL/min | 7 | 9 |
Incidence of renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| up to Month 6 | 0 | 0 |
| up to Month 12 | 0 | 0 |
Time to renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required
No measurements were reported for this outcome.
Incidence of acute rejection episodes at Month 6 and Month 12. This table counts multiple occurrences of rejection in the same patient as different incidents. Every incident is associated with both an A and a B classification. Classification A: Acute Rejection Grade 0 - none, Grade 1-minimal, Grade 2- mild, Grade 3-moderate, Grade 4-Severe; Classification B: Airway Inflammation-Grade 0-none, Grade 1R-low grade, Grade 2R-high grade, Grade X-ungradeable
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Up to 6 months: Classification A | 11 | 13 |
| Up to 6 months: Classification B | 11 | 13 |
| 6 to 12 months: Classification A | 10 | 9 |
| 6 to 12 months: Classification B | 10 | 9 |
Incidence of graft loss/re-transplantation at Month 6 and Month 12
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 6 | 0 | 0 |
| Month 12 | 1 | 1 |
Incidence of Bronchiolitis obliterans syndrome (BOS) at Month 6 and Month 12 BOS 0 is FEV1 \> 90% of baseline and FEF25-75% \> 75% of baseline; BOS 0-p is FEV1 81-90% of baseline and/or FEF25-75% ≤ 75% of baseline; BOS 1 is FEV1 66-80% of baseline; BOS 2 is FEV1 51-65% of baseline; BOS 3 is FEV1 ≤ 50% of baseline
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 6 - Total (all grades) | 66 | 61 |
| Month 6 - BOS 0 | 36 | 40 |
| Month 6 - BOS 0p | 26 | 14 |
| Month 6 - BOS 1 | 3 | 5 |
| Month 6 - BOS 2 | 1 | 0 |
| Month 6 - BOS 3 | 0 | 2 |
| Month 6 - BOS (>/=1) | 4 | 7 |
| Month 12 - Total (all grades) | 66 | 61 |
| Month 12 - BOS 0 | 35 | 38 |
| Month 12 - BOS 0p | 26 | 14 |
| Month 12 - BOS 1 | 3 | 5 |
| Month 12 - BOS 2 | 1 | 1 |
| Month 12 - BOS 3 | 1 | 3 |
| Month 12 - BOS (>/=1) | 5 | 9 |
Incidence of death at Month 6 and Month 12
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 6 | 0 | 0 |
| Month 12 | 3 | 1 |
Quality of Life (QoL, SF36) at Month 6 and Month 12 Scores can range from a minimum of 0 (maximum disability) to a maximum of 100 (no disability).
| scores on a scale | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 6: Physical component summary score | 46.9 ± 7.6 | 48.9 ± 7.3 |
| Month 6: Mental component summary score | 51.5 ± 10.8 | 52.6 ± 8.1 |
| Month 6: Physical functioning | 78.8 ± 20.9 | 84.1 ± 16.8 |
| Month 6: Role-Physical | 71.1 ± 23.2 | 77.1 ± 24.2 |
| Month 6: Bodily pain | 76.4 ± 27.9 | 81.3 ± 23.4 |
| Month 6: General health perception | 65.4 ± 19.2 | 70.6 ± 19.9 |
| Month 6: Vitality | 67.4 ± 18.0 | 70.0 ± 14.6 |
| Month 6:Social functioning | 84.1 ± 22.6 | 88.9 ± 17.6 |
| Month 6: Role-Emotional | 84.7 ± 22.4 | 84.8 ± 17.9 |
| Month 6: Mental health | 78.5 ± 17.2 | 81.0 ± 12.8 |
| Month 12: Physical component summary score | 47.2 ± 8.8 | 47.7 ± 7.1 |
| Month 12: Mental component summary score | 49.7 ± 11.8 | 53.8 ± 9.1 |
| Month 12: Physical functioning | 77.4 ± 21.8 | 82.5 ± 20.0 |
| Month 12: Role-Physical | 68.3 ± 26.8 | 78.0 ± 22.9 |
| Month 12: Bodily Pain | 76.8 ± 27.0 | 80.1 ± 22.7 |
| Month 12: General health perception | 66.7 ± 17.3 | 65.8 ± 20.3 |
| Month 12: Vitality | 65.7 ± 19.4 | 69.9 ± 17.5 |
| Month 12: Social functioning | 82.3 ± 23.0 | 90.5 ± 16.1 |
| Month 12: Role-Emotional | 79.4 ± 27.3 | 86.2 ± 20.5 |
| Month 12: Mental health | 75.4 ± 18.2 | 81.8 ± 14.8 |
Exercise capacity (6MWT) at Month 6 and Month 12 Measured by the Borg Scale. THE BORG SCALE 0 is Nothing at all, 0.5 is Very, very slight (just noticeable); 1 is Very slight, 2 is Slight (light); 3 is Moderate; 4 is Somewhat severe; 5 is Severe (heavy), 7 is Very severe, 10 is Very, very severe (maximal)The higher the Borg score implies increased shortness of breath and/or increased fatigue.
| Scores on a scale | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 6-Borg score - Before start of test | 0.47 ± 0.78 | 0.39 ± 0.77 |
| Month 6-Borg score - At end of test | 1.75 ± 1.58 | 1.64 ± 1.31 |
| Month 12-Borg score - Before start of test | 0.38 ± 0.94 | 0.42 ± 0.79 |
| Month 12-Borg score - At end of test | 2.08 ± 1.58 | 2.06 ± 1.85 |
Incidence of treated of arterial hypertension up to Month 12
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 2 | 1 |
| Month 3 | 2 | 1 |
| Month 6 | 2 | 1 |
| Month 9 | 3 | 1 |
| Month 12 | 4 | 1 |
Incidence of Diabetes Mellitus up to Month 12
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 0 | 0 |
| Month 3 | 0 | 0 |
| Month 6 | 0 | 1 |
| Month 9 | 1 | 1 |
| Month 12 | 1 | 1 |
Trough levels of everolimus at Month 1, 3, 6, 9, 12
| ng/mL | Quadruple Low Level IS Regimen |
|---|---|
| Month 1 | 4.2 ± 1.4 |
| Month 3 | 4.4 ± 1.2 |
| Month 6 | 4.1 ± 1.2 |
| Month 9 | 4.5 ± 1.6 |
| Month 12 | 4.3 ± 1.1 |
Adherence to target ranges of everolimus at Month 1, 3, 6, 9, 12
| participant adherence | Quadruple Low Level IS Regimen |
|---|---|
| Month 1 Below Target Range | 10 ± 1.4 |
| Month 1 Within Target Range | 42 ± 1.2 |
| Month 1 Above Target Range | 14 ± 1.2 |
| Month 3 Below Target Range | 5 ± 1.6 |
| Month 3 Within Target Range | 41 ± 1.1 |
| Month 3 Above Target Range | 15 |
| Month 6 Below Target Range | 7 |
| Month 6 Within Target Range | 39 |
| Month 6 Above Target Range | 12 |
| Month 9 Below Target Range | 5 |
| Month 9 Within Target Range | 34 |
| Month 9 Above Target Range | 13 |
| Month 12 Below Target Range | 3 |
| Month 12 Within Target Range | 38 |
| Month 12 Above Target Range | 9 |
Trough levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
| ng/mL | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 61 ± 21.83 | 106 ± 21.25 |
| Month 3 | 59.65 ± 20.43 | 109 ± 24.95 |
| Month 6 | 58.50 ± 12.84 | 103 ± 32.95 |
| Month 9 | 57.59 ± 23.26 | 107 ± 29.13 |
| Month 12 | 69.33 ± 48.41 | 108 ± 27.82 |
Adherence to target ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
| participant adherence | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 Below Target Range | 0 ± 21.83 | 8 ± 21.25 |
| Month 1 Within Target Range | 18 ± 20.43 | 8 ± 24.95 |
| Month 1 Above Target Range | 3 ± 12.84 | 0 ± 32.95 |
| Month 3 Below Target Range | 0 ± 23.26 | 4 ± 29.13 |
| Month 3 Within Target Range | 18 ± 48.41 | 10 ± 27.82 |
| Month 3 Above Target Range | 2 | 0 |
| Month 6 Below Target Range | 0 | 6 |
| Month 6 Within Target Range | 18 | 8 |
| Month 6 Above Target Range | 2 | 0 |
| Month 9 Below Target Range | 0 | 4 |
| Month 9 Within Target Range | 16 | 9 |
| Month 9 Above Target Range | 1 | 0 |
| Month 12 Below Target Range | 0 | 3 |
| Month 12 Within Target Range | 16 | 10 |
| Month 12 Above Target Range | 5 | 0 |
Trough levels of Tacrolimus at Month 1, 3, 6, 9, 12
| ng/mL | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 5.07 ± 1.80 | 10.44 ± 2.73 |
| Month 3 | 5.18 ± 2.02 | 10.53 ± 2.88 |
| Month 6 | 4.70 ± 1.98 | 10.09 ± 3.37 |
| Month 9 | 5.78 ± 4.18 | 10.67 ± 3.44 |
| Month 12 | 5.19 ± 2.36 | 9.66 ± 3.01 |
Adherence to target ranges of Tacrolimus at Month 1, 3, 6, 9, 12
| participant adherence | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 Below Target Range | 3 ± 21.83 | 0 ± 21.25 |
| Month 1 Within Target Range | 24 ± 20.43 | 45 ± 24.95 |
| Month 1 Above Target Range | 17 ± 12.84 | 0 ± 32.95 |
| Month 3 Below Target Range | 3 ± 23.26 | 0 ± 29.13 |
| Month 3 Within Target Range | 23 ± 48.41 | 47 ± 27.82 |
| Month 3 Above Target Range | 18 | 0 |
| Month 6 Below Target Range | 5 | 1 |
| Month 6 Within Target Range | 23 | 45 |
| Month 6 Above Target Range | 12 | 0 |
| Month 9 Below Target Range | 2 | 0 |
| Month 9 Within Target Range | 18 | 46 |
| Month 9 Above Target Range | 18 | 0 |
| Month 12 Below Target Range | 3 | 0 |
| Month 12 Within Target Range | 23 | 47 |
| Month 12 Above Target Range | 15 | 0 |
Incidence of bacterial, viral, and fungal infections at Month 12
| incidences | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Bacterial infections | 3 | 4 |
| Viral infections | 14 | 20 |
| Fungal infections | 3 | 0 |
Triglyceride levels at Month 1, 3, 6, 9, 12
| mmol/L | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 2.6 ± 1.4 | 2.0 ± 0.9 |
| Month 3 | 2.7 ± 1.3 | 2.1 ± 1.0 |
| Month 6 | 2.6 ± 1.2 | 2.0 ± 1.1 |
| Month 9 | 2.7 ± 1.3 | 2.0 ± 1.0 |
| Month 12 | 2.7 ± 1.5 | 2.1 ± 0.9 |
Total Cholesterol levels at Month 1, 3, 6, 9, 12
| mmol/L | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 0.8 ± 0.8 | -0.2 ± 0.7 |
| Month 3 | 1.0 ± 0.8 | -0.1 ± 0.9 |
| Month 6 | 1.1 ± 0.9 | -0.2 ± 0.8 |
| Month 9 | 1.1 ± 0.9 | -0.1 ± 0.9 |
| Month 12 | 0.8 ± 1.1 | -0.1 ± 0.8 |
LDL Cholesterol levels at Month 1, 3, 6, 9, 12
| mmol/L | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 0.4 ± 0.8 | 0.0 ± 0.5 |
| Month 3 | 0.6 ± 0.7 | -0.0 ± 0.6 |
| Month 6 | 0.7 ± 0.8 | -0.0 ± 0.6 |
| Month 9 | 0.8 ± 0.8 | 0.1 ± 0.7 |
| Month 12 | 0.5 ± 0.9 | 0.1 ± 0.6 |
HDL Cholesterol levels at Month 1, 3, 6, 9, 12
| mmol/L | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| Month 1 | 0.1 ± 0.3 | -0.1 ± 0.3 |
| Month 3 | 0.1 ± 0.3 | -0.0 ± 0.4 |
| Month 6 | 0.1 ± 0.4 | -0.0 ± 0.4 |
| Month 9 | 0.0 ± 0.4 | -0.0 ± 0.4 |
| Month 12 | 0.0 ± 0.5 | -0.0 ± 0.4 |
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until 12 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Quadruple Low Level IS Regimen | — | 29/67 (43.3%) | 62/67 (92.5%) |
| Centre Specific Triple IS Regimen | — | 22/63 (34.9%) | 58/63 (92.1%) |
| Event | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| FORCED EXPIRATORY VOLUME DECREASEDInvestigations | 9/67 | 5/63 |
| LUNG TRANSPLANT REJECTIONImmune system disorders | 5/67 | 0/63 |
| CYTOMEGALOVIRUS INFECTIONInfections and infestations | 1/67 | 4/63 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 3/67 | 4/63 |
| PYREXIAGeneral disorders | 4/67 | 3/63 |
| PNEUMONIAInfections and infestations | 3/67 | 3/63 |
| RESPIRATORY TRACT INFECTIONInfections and infestations | 1/67 | 3/63 |
| CHEST PAINGeneral disorders | 3/67 | 0/63 |
| OEDEMA PERIPHERALGeneral disorders | 3/67 | 0/63 |
| INFECTIONInfections and infestations | 3/67 | 2/63 |
| Event | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen |
|---|---|---|
| LEUKOPENIABlood and lymphatic system disorders | 15/67 | 19/63 |
| OEDEMA PERIPHERALGeneral disorders | 19/67 | 10/63 |
| NASOPHARYNGITISInfections and infestations | 17/67 | 17/63 |
| ACNESkin and subcutaneous tissue disorders | 12/67 | 1/63 |
| CYTOMEGALOVIRUS INFECTIONInfections and infestations | 10/67 | 11/63 |
| DIARRHOEAGastrointestinal disorders | 9/67 | 10/63 |
| NAUSEAGastrointestinal disorders | 9/67 | 10/63 |
| COUGHRespiratory, thoracic and mediastinal disorders | 10/67 | 7/63 |
| HEADACHENervous system disorders | 8/67 | 9/63 |
| FORCED EXPIRATORY VOLUME DECREASEDInvestigations | 7/67 | 8/63 |
| Age, Continuous(years) | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen | Total |
|---|---|---|---|
| Mean | 53.9 ± 9.5 | 54.2 ± 9.2 | 54.0 ± 9.3 |
| Sex: Female, Male(Participants) | Quadruple Low Level IS Regimen | Centre Specific Triple IS Regimen | Total |
|---|---|---|---|
| Female | 27 | 22 | 49 |
| Male | 40 | 41 | 81 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Feb 2012 to primary completion in Jan 2017, 59 months.
Results were first posted in Mar 2019, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus